Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blossom: Ranibizumab in BRVO-ME
NCT01976338Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2013
- Primary completion
- Mar 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of ranibizumab in macular edema, sponsored by Novartis. Started Nov 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01976338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01976338.